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SUMMARY
Aim
To assess primary care physician perceptions of non-steroidal anti-
inflammatory drug (NSAID) and aspirin-associated toxicity.
Methods
A group of gastroenterologists and internal medicine physicians created
a survey, which was administered via the Internet to a large number of
primary care physicians from across the US.
Results
One thousand primary care physicians participated. Almost one-third of
primary care physicians recommended 325 mg rather than 81 mg of
aspirin/day for cardioprotection. Fifty-nine percent thought enteric-coa-
ted or buffered aspirin reduced the risk of upper gastrointestinal (GI)
bleeding. Seventy-six percent believed that Helicobacter pylori infection
increased the risk of NSAID ulcers but fewer than 25% tested NSAID
users for this infection. More than two-thirds were aware that aspirin
co-therapy decreased the GI safety benefits of the cyclo-oxygenase 2
selective NSAIDs. However, 84% felt that aspirin with a cyclo-oxyge-
nase 2 selective NSAID was safer than aspirin with a non-selective
NSAID. When presented a patient at high risk for NSAID-related GI tox-
icity, almost 50% of primary care physicians recommended a proton
pump inhibitor and cyclo-oxygenase 2 selective NSAID.
Conclusions
This survey has identified areas of misinformation regarding the risk–
benefit of NSAIDs and aspirin and the utilization of gastroprotective
strategies. Further education on NSAIDs for primary care physicians is
warranted.
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INTRODUCTION
There is a considerable morbidity and mortality associ-
ated with non-steroidal anti-inflammatory drug
(NSAID)-related gastrointestinal injury.1 Based upon
data from the US, over 111 million prescriptions for
anti-inflammatory drugs were written in 2004, with
additional patient exposure in the over-the-counter
(OTC) NSAID market, translating to an enormous
cohort at risk.2
Estimates of as many as 107 000 hospitalizations
and 16 500 deaths result from NSAID-induced serious
adverse events in the US alone.3 These untoward
events are of importance not only in terms of the
resultant morbidity and mortality; but also such com-
plications incur substantial resource use.4
Primary care physicians (PCPs) prescribe a substan-
tial proportion of NSAIDs. However, dissemination and
incorporation of new information in this rapidly evol-
ving field can be slow and is subject to the influence
of promotional efforts initiated by the pharmaceutical
industry, which not only target providers but have
aggressively marketed innovations in this area directly
to consumers.
Non-steroidal anti-inflammatory drugs are inhibitors
of cyclo-oxygenase (COX), which has at least two iso-
forms: cyclo-oxygenase 1 (COX-1) and cyclo-oxyge-
nase 2 (COX-2). Traditional ‘non-selective’ NSAIDs
and aspirin antagonize the actions of both COX-1 and
-2. Their depletion of gastrointestinal mucosal prosta-
glandins explains their gastrointestinal toxicity. The
COX-2-selective NSAIDs have been shown in large
outcome studies to be associated with lower rates of
upper and lower gastrointestinal (GI) adverse events
than non-selective NSAIDs5 – but only among patients
who do not concomitantly use aspirin.6–7
The efficacy of non-selective and COX-2-selective
NSAIDs in treating pain and inflammation should be
considered in concert with their recognized gastroin-
testinal toxicity and increasingly, with consideration
of their cardiovascular risk.8–9 The gastrointestinal
risks – at least those in the upper GI tract – can be
reduced by the concomitant prescription of a ‘gastro-
protective’ agent such as a proton pump inhibitor (PPI)
or misoprostol.10–11
To better understand the perceptions of the potential
risks associated with the use of aspirin, non-selective
and COX-2-selective NSAIDs, and the use of gastro-
protective strategies, we conducted a survey research
study amongst a large, geographically diverse group
of PCPs from the US. Our data were collected late in
2003 prior to the withdrawal of rofecoxib and valdec-
oxib. Although a great deal of attention has subse-
quently been focused on the cardiovascular risk
associated with the COX-2-selective NSAIDs, a number
of other important issues regarding the use of aspirin,
NSAIDs and gastroprotective medications remain.
The results of this survey serve to identify a
number of areas which require further clarification
and education.
METHODS
The questionnaire was developed by the investigators
without influence from the pharmaceutical sponsor.
The items elicited information regarding PCP practices
and perceptions on aspirin, NSAID and gastroprotec-
tive medication use.
Study population
A PCP was defined as a general practitioner, family
practitioner or internal medicine physician. Three
thousand, eight hundred and sixteen PCPs from a
panel provided by a professional Internet survey
research organization (Ziment, New York, NY, USA)
were invited to participate. Potential study participants
were solicited by e-mail. Those that opted to partici-
pate were asked several screening questions to be sure
that they were appropriate for the survey. In order to
participate, PCPs had to have been practising medicine
in the US for at least two but no more than 35 years,
to spend no more than 50% of their time in a teaching
capacity, and to write at least 15 prescriptions per
month for the management of pain or inflammation.
Exclusion criteria included working for (or having an
immediate family member who worked for) an adverti-
sing agency, marketing company, pharmaceutical
company or news organization. Those that did not
meet the screening criteria were not allowed to com-
plete the survey.
A geographically diverse cohort of 1000 PCPs
completed the on-line survey anonymously from
November 20 through December 8, 2003. Solicitation
was closed after 1000 completed questionnaires were
obtained. A fee of $25 was offered for completing the
survey. Funding for the services provided by the
survey research organization and participant honoraria
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were provided by TAP Pharmaceuticals (Chicago, IL,
USA).
Survey administration
The order of questions presented in the survey can be
found in the Appendix. Participants could only
proceed to the next question after completing the
question currently on their computer monitor. Once a
question was completed and the participant proceeded
to the next question, they could not go back and
change an answer to a previous question. Participants
were neither encouraged nor discouraged to use refer-
ence materials when completing the survey.
Questionnaire content
Aspirin issues
Questions probed beliefs regarding the efficacy of
aspirin as a primary or secondary prevention strategy
for myocardial infarction (MI) and stroke as well as
prescribing behaviours (recommended dose and fre-
quency of prescribing) of aspirin for those indications.
Participants were asked if enteric-coated or buffered
aspirin reduced the likelihood of developing an upper
GI-bleeding event compared with regular aspirin.
A hypothetical situation was posed involving a
patient with a history of an ulcer-related upper GI
bleed that required low-dose aspirin for a history of
coronary artery disease. Participants were asked to
choose between continuing the aspirin without any
change in therapy, switching to enteric-coated aspirin,
adding an H2-receptor antagonist (H2RA) in a dose
available for OTC purchase, adding an H2RA at pre-
scription strength, adding a PPI, or adding misoprostol.
Utilization of non-selective NSAIDs and associated
risks
The questionnaire queried about how often elderly
patients (>70 years) used NSAIDs, the type of NSAID
an individual PCP most often prescribed, and the gas-
trointestinal risks of COX-2-specific agents compared
with non-selective NSAIDs. Participants were asked
their belief on whether the presence of dyspeptic
symptoms identified patients more likely to develop an
NSAID-associated ulcer complication and whether
non-selective NSAIDs are associated with an increased
risk of bleeding from the small intestine and/or colon.
NSAIDs and Helicobacter pylori infection
To asses the level of understanding of the relationship
between NSAIDs and H. pylori, we asked if the pres-
ence of H. pylori would reduce, increase or have no
net effect on the likelihood of ulcers in NSAID users.
Participants were also asked about the frequency of
testing for H. pylori in patients taking NSAIDs.
Utilization and safety of COX-2-selective NSAIDs
Participants were asked if COX-2-selective NSAIDs
reduced the likelihood of significant adverse GI events
such as bleeding, perforation or obstruction compared
with non-selective NSAIDs. They were also asked if
the GI safety benefits of the COX-2-selective NSAIDs
were maintained in patients concurrently taking low-
dose aspirin. Beliefs about the possibility of increased
cardiovascular risks associated with rofecoxib were
also assessed. We asked PCPs if they felt that rofec-
oxib was associated with an increased risk of MI and
if the potential for adverse cardiac effects influenced
their decision to prescribe this medication.
Hypothetical patient scenarios
To better understand the strategies employed by PCPs to
reduce the risk of an NSAID-associated GI complication,
a series of hypothetical patient scenarios were construc-
ted. These patient scenarios were designed to assess how
PCPs apply their knowledge of the risks and benefits of
aspirin, NSAIDs and gastroprotective medications in
clinical practice situations. PCPs were asked what they
would recommend for the following patient scenarios:
(i) ‘A patient, with a recently healed H. pylori negat-
ive, NSAID-associated ulcer, who requires an NSAID
for joint pain’. Choices offered included change to a
COX-2-selective NSAID, add a PPI, change to a COX-
2-selective NSAID and add a PPI, add misoprostol, add
a H2RA, add sucralfate or use an alternative traditional
NSAID and a PPI.
(ii) ‘A patient, with a history of previous MI, who
requires low-dose aspirin for cardioprotection and an
NSAID for arthritis related pain’. Options offered to
study participants included aspirin and a traditional
NSAID; aspirin with a traditional NSAID and PPI;
aspirin with a traditional NSAID and misoprostol;
aspirin with a traditional NSAID and a H2RA; aspirin
with a COX-2-selective NSAID; or aspirin with a COX-
2-selective NSAID and PPI.
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(iii) ‘A patient, with a past history of an ulcer-rela-
ted upper gastrointestinal bleed, who needs to be on
an NSAID for joint pain and also needs low-dose aspi-
rin for a history of coronary artery disease’. For this
question, PCPs chose from aspirin with a traditional
NSAID; aspirin with a traditional NSAID and PPI;
aspirin with a traditional NSAID and misoprostol;
aspirin with a traditional NSAID and H2RA; aspirin
with a COX-2-selective NSAID; or aspirin with a COX-
2-selective NSAID and PPI.
Statistical analysis
Descriptive statistics characterized the responses to the
questionnaire.
Comparisons between subgroups of the study sample
(gender-, age- and region-based comparisons) were
performed using the chi-squared test (QUANTUM soft-
ware; SPSS, Chicago, IL, USA). In situations where
answers to a question created a continuous variable, a
Student’s t-test was utilized. A P-value of less than
0.05 defined a statistically significant difference
between values. When present, significant differences
in the data based upon the gender, age, and region of
residence are mentioned in the results section.
RESULTS
Demographics
Table 1 summarizes the demographic data for the
1000 respondents. Eighty percent of respondents were
male. A discussion of how our sample compared with
PCPs at large and the limitations of our survey meth-
odology can be found in the Discussion section. Most
PCPs reported insurance coverage for their patients:
24% Health Maintenance Organization, 20% Preferred
Provider Organization, 8% Point of Service, 27%
Medicare and 8% Medicaid.
Aspirin issues
Consistent with the recently published US Preventive
Services Task Force document, ninety-one percent of
PCPs felt that aspirin had been shown to be effective in
the primary prevention of MI.12 Though the available
evidence would suggest otherwise, 85% felt that aspirin
had been shown to be of benefit for the primary pre-
vention of stroke.12 Sixty-two percent of participants
reported that they always recommended aspirin for the
primary prevention of MI. Ninety-five percent recom-
mended aspirin for primary prevention of MI always or
most of the time (>50% of the time). Ninety-one per-
cent recommended aspirin all or most of the time
for the primary prevention of stroke. These recommen-
dations were not influenced by the gender, age or
region of residence of the respondents. Nearly a third
recommended aspirin 325 mg daily rather than 81 mg
daily for the primary prevention of MI (Figure 1). PCPs
under the age of 55 years recommended the higher
dose of aspirin more commonly than PCPs over the age
of 55 years (32% vs. 20%, P ¼ 0.0035). For their
patients requiring aspirin for cardioprotection, 59% of
participants thought enteric-coated or buffered aspirin
reduced the risk of serious upper GI-bleeding events
despite a lack of evidence to support this belief. More
female than male PCPs believed that enteric coating or
buffering of aspirin reduced the risk of developing a
serious gastrointestinal bleeding event (67% vs. 57%,
P ¼ 0.0094). When presented a patient with known
cardiac disease and a history of previous upper gastro-
intestinal bleeding but no current dyspeptic symptoms,
53% of participants recommended switching from
non-coated to enteric-coated aspirin while only 26%
recommended the addition of a PPI. Perhaps more dis-
turbingly, 9% recommended no change in therapy. The
remaining 12% suggested the addition of an OTC or
prescription H2RA or misoprostol.
Utilization of non-selective NSAIDs and
associated risks
Fifty percent of participants reported that over half of
their patients older than age 70 years used an NSAID
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at least once per week while 42% said that the correct
percentage of weekly NSAID users was between 30%
and 50%. Participants reported 57% of their NSAID
prescriptions were for a non-selective agent while 43%
of their NSAID prescriptions were for a COX-2-select-
ive NSAID. Younger PCPs were less likely than older
PCPs to recommend a COX-2-selective NSAID than a
traditional NSAID (42% vs. 47%, P ¼ 0.005). PCPs
from the west coast (37%) were less likely to prescribe
a COX-2-selective NSAID than their counterparts from
the northeast (42%), south (44%) or central states
(45%).
Despite data to the contrary,13–14 more than a third
(34%) believed that most patients who developed
upper gastrointestinal bleeding while taking NSAID
experienced antecedent dyspeptic symptoms. Seventy-
six percent of participants were aware that NSAIDs
increased the risk of bleeding from the small intestine
and/or colon. Responses were similar regardless of the
gender, age or region of residence of the respondents.
NSAIDs and H. pylori infection
Seventy-six percent of participants believed that the
presence of H. pylori infection increased the likelihood
of an NSAID-associated ulcer while 19% felt that
H. pylori played no role. Three percent actually felt
that H. pylori decreased the risk of an NSAID-associ-
ated ulcer. PCPs over the age of 55 years were more
likely than those <55 years to believe that H. pylori
increased the likelihood of ulcers in NSAID users (88%
vs. 76%, P ¼ 0.0009). Though the majority of PCPs
felt that H. pylori increased the risk of developing an
NSAID-associated ulcer, fewer than a quarter recom-
mended testing for this infection in patients initiating
or already taking NSAID therapy. Opinions on testing
for H. pylori before starting an NSAID or in those
patients already on an NSAID are presented in Fig-
ure 2. Responses to questions in this section of the
questionnaire were not influenced by the gender or
residence of the respondents.
Utilization and safety of COX-2-selective
NSAIDs
Ninety-four percent of participants believed that COX-
2-selective agents reduced the likelihood of adverse
GI events compared to non-selective NSAIDs. Sixty-
four percent of the PCPs were aware that co-therapy
with aspirin decreased the GI safety benefits offered
by the COX-2-selective NSAIDs while 26% felt that
aspirin had no effect and 5% actually felt that aspirin
improved the GI safety benefits of these agents. A
greater percentage of older than younger PCPs
believed that low-dose aspirin had no effect on the
gastrointestinal safety benefits of a COX-2-selective
NSAID (33% vs. 24%, P ¼ 0.0317). However, despite a
lack of evidence, an overwhelming majority (84%)
felt that aspirin combined with a COX-2-selective
NSAID was safer than aspirin combined with a
non-selective NSAID. Only 6% of PCPs felt that rofec-
oxib was associated with a higher likelihood of MI
than other COX-2-selective NSAIDs while 57% felt
that the cardiovascular risk for rofecoxib was no
greater than for other COX-2-selective NSAIDs.
Twelve percent reported that concern over cardiovas-
cular safety with rofecoxib influenced their prescri-
bing behaviour while 48% stated that such concerns
did not influence their prescribing of rofecoxib. Gen-
der, age or residence of PCP did not influence the
responses.
Hypothetical patient scenarios
Figures 3–5 detail the respondents’ recommendations
for the three hypothetical patient scenarios described
in the methods section. As seen in Figure 3 nearly half
of PCPs recommended the combination of a COX-
selective NSAID and a PPI in a patient with recent
NSAID-associated ulcer bleeding. Approximately a
fifth of respondents recommended either adding a PPI
to a non-selective NSAID or using a COX-2-selective
NSAID alone in this patient.
For the patient with cardiac disease in need of anti-
platelet therapy and an NSAID for joint pain (Figure 4),






Figure 1. Dose of aspirin recommended by primary care
physicians for cardioprotection.
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combination of aspirin and a COX-2-selective NSAID
while over a quarter recommended aspirin with a non-
selective NSAID. Physicians over the age of 55 more
commonly recommended aspirin and a COX-2-select-
ive NSAID than those under the age of 55 years (57%
vs. 43%, P ¼ 0.0014). Fourteen percent recommended
aspirin with a COX-2-selective NSAID and PPI. Only
9% selected the combination of aspirin, non-selective
NSAID and PPI.
Finally, for the patient with a recent ulcer bleed
who requires antiplatelet therapy for cardioprotection
and an NSAID for joint pain (Figure 5), 60% chose
aspirin, a COX-2-selective NSAID and a PPI. Some-
what disturbingly, a quarter selected the combination
of aspirin and a COX-2-selective NSAID. Only 9%
selected aspirin, a non-selective NSAID and a PPI.
DISCUSSION
Our survey identified some significant gaps in know-
ledge regarding the risks and benefits of aspirin and
NSAID therapy. Further, this data raises some interest-
ing questions regarding the utilization of gastroprotec-
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Figure 2. Respondents’ use of Helicobacter pylori testing
















Figure 3. Recommended changes for a patient with a
recent ulcer-related upper GI bleed who needs an NSAID
for joint pain. Asa ¼ Aspirin, COXIB ¼ COX 2 selective























Figure 4. Recommended changes for a patient with no
history of ulcer bleeding who needs aspirin for cardiopro-
tection and an NSAID for joint pain. Asa ¼ Aspirin,





















Figure 5. Recommended changes for a patient with a his-
tory of a previous ulcer-related upper GI bleed who needs
aspirin for cardioprotection and an NSAID for joint pain.
Asa ¼ Aspirin, COXIB ¼ COX 2 selective NSAID, PPI ¼
proton pump inhibitor.
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Aspirin use, either with of without the advice of a
physician, is increasing in the US.15 The potential risks
associated with the use of low-dose aspirin appear to
be under-recognized by both consumers and health-
care providers. Although a dose as low as 75 mg per
day has been shown to offer cardioproctective bene-
fit,12, 16 many consumers take larger doses, presumably
in the belief that benefit is dose-related and because
the higher dose has a lower acquisition cost. Unfortu-
nately, this may increase the GI risk without adding
additional cardiovascular benefit.17 To this point,
nearly one-third of our primary care participants
recommended daily doses of aspirin greater than
81 mg per day for cardioprotection. Further, a signifi-
cant percentage of PCPs reported that they typically
recommended aspirin for primary prevention of car-
diac events in all patients. Although antiplatelet ther-
apy, particularly aspirin, has been found to
significantly reduce recurrent cardiovascular and vas-
cular events (secondary prevention – those with a
prior cardiovascular or vascular event), its role in pri-
mary prophylaxis (those with no history of a cardio-
vascular or vascular event) remains the subject of
some debate.12, 16 It is clear that the benefits of aspirin
must be weighed against the potential problems that
such treatment can induce. Even low doses of aspirin
can have detrimental effects on the gastric mucosa.
When combined with the antiplatelet effects of aspirin,
it is not surprising that a meta-analysis of 24 random-
ized trials involving over 66 000 patients reported a
2-fold increase in the risk of gastrointestinal bleeding
for those taking chronic low-dose aspirin compared to
those not taking aspirin.18 In addition, aspirin use may
be associated with an increased risk of haemorrhagic
stroke. These well-documented safety concerns led the
US Preventative Services Task Force to recommend
that a risk–benefit calculation be performed before
recommending low-dose aspirin for primary preven-
tion of cardiovascular events. The Task Force conclu-
ded that the balance of risk and benefit of aspirin was
strongly tied to cardiac risk, explicitly recommending
prophylactic aspirin only to those with a 3% or greater
five year risk of cardiovascular events. Calculation of
such risk is easily performed using Personal Digital
Assistant or Internet based tools.12, 16
Surprisingly, fewer than one-third of PCPs recom-
mended an accepted gastroprotective agent for aspirin
users at high risk for a GI complication. This is con-
cerning as a recent trial from Hong Kong19 reported
that patients with a history of aspirin-associated ulcer
bleeding who were continued on low-dose aspirin
without a gastroprotective agent had a one year ulcer
rebleeding risk of approximately 15%. On the other
hand, the addition of a PPI to aspirin was associated
with a significant reduction in the annual recurrence
of ulcer rebleeding. Further, more than half (53%) of
our survey respondents recommended switching from
regular aspirin to enteric coated aspirin rather than
adding a gastroprotective agent in patients with a his-
tory of an aspirin-associated UGI bleed who require
cardioprotection. Available data suggests that enteric-
coating or buffering of aspirin does not reduce the risk
of upper GI bleeding.18, 20 To date, there have been no
placebo-controlled, randomized trials with misoprostol
or histamine-2-recpetor antagonists in high risk
patients taking aspirin.
Nearly one quarter of participants was unaware of the
deleterious effects that aspirin exerts on the GI safety
benefits of the COX-2-selective NSAIDs.6–7, 21 Eighty-
four percent thought that adverse GI events would be
less likely with the combination of low-dose aspirin and
a COX-2-selective NSAID compared to low-dose aspirin
and a non-selective NSAID. While there are no pros-
pective randomized controlled trials which have
addressed this issue as a primary endpoint, the results of
secondary analyses and database studies suggest that
aspirin with a COX-2-selective NSAID are associated
with a similar risk of ulcer and upper GI bleeding as a
non-selective NSAID.22 Despite these deleterious effects
of aspirin on the GI safety benefits of the COX-2-select-
ive NSAIDs, 24% of our participants recommended the
combination of aspirin and a COX-2-selective NSAID
for a hypothetical patient with GI risk factors – without
the addition of a gastroprotective agent (Figure 5).
With regard to H. pylori infection in patients taking
an NSAID, 78% of PCPs believed there was a relation-
ship between H. pylori and the presence of NSAID
associated ulcers. While there appears to be an additive
risk of complications in infected individuals using an
NSAID,23 76% of practitioners never or rarely tested
for the presence of H. pylori before starting a NSAID.
A similar percentage of PCPs reported that they never
or rarely tested for the presence of H. pylori in those
already taking chronic NSAID therapy. This likely
reflects several issues including the lack of any formal
recommendation to address H. pylori in NSAID users
from professional organizations in the US, conflicting
data regarding the benefits of treating H. pylori in
NSAID users,24–27 and the complexity of testing and
eradication regimens for H. pylori infection.28
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In this survey which was performed prior to the
removal of 2 of the 3 available COX-2-selective
NSAIDs from the US market, PCPs appeared to use
COX-2-selective NSAIDs as first line therapy. In fact,
PCPs reported that 43% of their NSAID prescriptions
were for the COX-2-selective NSAIDs. This is somewhat
curious given modeling studies which have clearly
demonstrated that these agents are only cost-effective
in patients at higher risk for an NSAID associated gas-
trointestinal complication.29–30 At the time of our sur-
vey, less than 5% of PCPs felt that rofecoxib was
associated with a greater risk of MI than other COX-2-
selective NSAIDs and only 12% reported that these
concerns significantly influenced their decision to pre-
scribe rofecoxib. These findings are fascinating given
the reports of an increased incidence of MI with rofec-
oxib dating back to publication of the VIGOR trial in
20005 and subsequently raised by other analyses prior
to the time of our survey.31
The hypothetical patient scenarios also warrant
comment. At the time of our survey, many PCPs were
recommending the use of a COX-2-selective NSAID
with a PPI in patients at high risk for an NSAID rela-
ted complication. Though there was data to suggest
that the combination of a PPI and non-selective
NSAID or a COX-2-selective NSAID alone was associ-
ated with a lower rate of gastrointestinal complications
than a non-selective NSAID alone, there was no data
to suggest an incremental benefit to combining a PPI
and a COX-2-selective NSAID in late 2003. Subse-
quent data suggest that patients with a previous ulcer
bleed who receive a non-selective NSAID and PPI or
COX-2-selective NSAID alone may have a 6 month
ulcer recurrence and/or rebleeding rate as high of 24–
32%.11 Given this high rate of recurrent complications
and recently published economic data,32 it appears
reasonable to suggest the combination of a COX-2-
selective NSAID and PPI in such high risk patients. In
the 2 scenarios where a patient required an aspirin for
cardioprotection and an NSAID for joint pain, it is
interesting that such a high percentage of PCPs recom-
mended aspirin with a COX-2-selective NSAID, despite
the fact that more than two-thirds understood that
aspirin decreased or eliminated the GI safety benefits
of a COX-2-selective NSAID. This highlights the dis-
tressing fact that factual knowledge does not always
translate into clinical practice. It is not clear how
recent events surrounding the COX-2-selective NSAIDs
have affected prescribing patterns amongst PCPs
though one would speculate that utilization of gastro-
protective medications is likely to have replaced at
least some of the use of the COX-2-selective NSAIDs
in high risk patients.
The greatest strength of this study is the large,
nationally representative sample of physicians that
participated. As with any survey, our study has a
number of limitations. We contacted a large group of
PCPs by e-mail, which likely biased our study popula-
tion toward younger PCPs with access to and who
regularly used e-mail. Our demographic data confirms
this as only 1% of our participants were over the age
of 65 years. Amongst members of the American Med-
ical Association (not stratified by specialty), 18% were
over the age of 65 years. We cannot say for certain
how this may have affected our results. However, we
would argue that younger physicians who are held to
recently imposed recertification standards are likely to
be more up to date on new medical findings than their
older colleagues. We also note that 80% of our study
cohort was male. This is similar to data from the AMA
in 2000 which reported that 76% of its membership
was male .33 Unfortunately, we have no demographic
information about those who chose not to participate.
It is possible that our participants were more interested
in the subject of the survey than those who did not
participate. However if that were the case, our results
should represent the views of relatively well-informed
PCPs in the US and thus makes the results even more
compelling. The results reflect doctors’ self-reported
practice patterns, practices that are not verified by
chart reviews. Doctors may either overestimate or
underestimate their practices depending on behaviours
that might be perceived as incorrect or not standard of
care. Another point worthy of consideration is that we
did not encourage or discourage PCPs to use resource
materials when completing the survey. We feel this
reflects real life where PCPs can readily access refer-
ence materials if a question arises in their clinical
practice. Though there is no way to definitively know
whether or not PCPs utilized resource materials, we
were able to gauge how long it took individual
respondents to complete the survey. Presumably, those
taking an excessive amount of time to complete the
survey may have been more likely to have utilized ref-
erence materials. We have reviewed this data and time
to complete the survey fell within a very tight range
with no obvious outliers. As such, we do not feel that
the use of reference materials adversely affected the
results of our survey. Further, and perhaps most
importantly, if PCPs had utilized reference materials,
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one would expect an artificially increased reporting of
‘correct’ answers to survey questions and that is not
what we found.
We would also point out that there is no flawless
way to select a participant pool for a survey study.
Using a mass mailing to the membership of organiza-
tions such as the American Medical Association
(AMA) or American College of Physicians (ACP) may
not be truly representative of PCPs. For example, sur-
veying members of the ACP would capture primarily
internists and would largely ignore Family Medicine
physicians and General Practitioners. Further, survey
research studies which rely on mass mailings are typ-
ically associated with poor response rates raising
issues of generalizability of results.
Given the recent withdrawal of two COX-2-selective
NSAIDs from the US market because of adverse car-
diovascular events, a better understanding regarding
approaches to reducing ulcer risk has greater import-
ance than ever for physicians treating patients in need
of an NSAID or aspirin. Our survey has uncovered a
number of important areas of misinformation regard-
ing this complex treatment area which requires an
appropriate understanding of the benefits and risks
associated with these commonly used agents. Identify-
ing and addressing the existing knowledge deficits
offers the opportunity to reduce adverse events and
improve outcomes in patients who require an NSAID
and/or aspirin.
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NSAID USAGE ANALYSIS STUDY
Main questionnaire
I Treatment Behaviours
See Appendix for product and terminology chart. this chart will be shown to all physicians at the start of the
main questionnaire.
1. How often do you recommend aspirin as primary preventive therapy for:
Always Most of the time (>50% of time) Sometimes (<50% of time) Never
Myocardial infarction
(MI) in subjects
over the age of 60
4 3 2 1
Stroke in subjects
over the age of 60
4 3 2 1
2. When you recommend the use of aspirin for patients with cardiac disease, what dose do you typically recom-
mend?
325 mg per day ....................................................................................................................................... 1
325 mg every other day ......................................................................................................................... 2
81 mg per day ......................................................................................................................................... 3
81 mg every other day ........................................................................................................................... 4
3. For a patient with a history of an ulcer-related upper GI bleed in the past but has no current GI symptoms
who needs to be on low-dose aspirin for a history of coronary artery disease, what would you most likely recom-
mend?
Continue the aspirin without change in therapy ............................................................................... 1
Switch to enteric coated aspirin ........................................................................................................... 2
Add an OTC strength H2RA for symptoms only ................................................................................ 3
Add prescription strength H2RA therapy ............................................................................................ 4
Add a PPI ................................................................................................................................................. 5
Add misoprostol (Cytotec) ..................................................................................................................... 6
4. When treating a patient with H. pylori-negative, NSAID-associated gastric ulcer, which do you typically
recommend?
Sucralfate (Carafate) ............................................................................................................................... 1
PPI ............................................................................................................................................................. 2
H2RA ......................................................................................................................................................... 3
Misoprostol (Cytotec) .............................................................................................................................. 4
5. When treating a patient with H. pylori-negative, NSAID-associated duodenal ulcer, which do you typically
recommend?
Sucralfate (Carafate) ............................................................................................................................... 1
PPI ............................................................................................................................................................. 2
H2RA ......................................................................................................................................................... 3
Misoprostol (Cytotec) .............................................................................................................................. 4
6. When attempting to reduce the likelihood of recurrent ulcer related bleeding in a patient with a recently
healed H. pylori negative, NSAID-associated ulcer, who requires the NSAID for joint pain, which would you most
likely recommend (assuming the patient was on a traditional NSAID)?
Add sucralfate (Carafate) ....................................................................................................................... 1
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Add a PPI ................................................................................................................................................. 2
Add an H2RA ........................................................................................................................................... 3
Add Misoprostol (Cytotec) ..................................................................................................................... 4
Change to COX-2-selective NSAID ...................................................................................................... 5
Change to COX-2-selective NSAID+ PPI ............................................................................................. 6
Change to an alternate traditional NSAID + PPI ............................................................................... 7
7. In a subject with a history of previous MI who requires low-dose aspirin for cardioprotection and an NSAID
for arthritis related pain, which would you most likely recommend (assuming the subject has no other risk factors
for an NSAID associated GI complication)?
Aspirin and a traditional NSAID .......................................................................................................... 1
Aspirin and a traditional NSAID with an H2RA ................................................................................ 2
Aspirin and a traditional NSAID with a PPI ...................................................................................... 3
Aspirin and a traditional NSAID with misoprostol (Cytotec) .......................................................... 4
Aspirin and a COX-2-selective agent (instead of the traditional NSAID) ..................................... 5
Aspirin and a COX-2-selective agent (instead of the traditional NSAID) with a PPI .................. 6
8. In a patient with a past history of an ulcer-related upper GI bleed who needs to be on an NSAID for joint
pain and also needs low-dose aspirin for a history of coronary artery disease, what would you most likely recom-
mend to reduce the likelihood of recurrent ulcer bleeding?
Aspirin and a traditional NSAID .......................................................................................................... 1
Aspirin and a traditional NSAID with an H2RA ................................................................................ 2
Aspirin and a traditional NSAID with a PPI ...................................................................................... 3
Aspirin and a traditional NSAID with misoprostol (Cytotec) .......................................................... 4
Aspirin and a COX-2-selective agent (instead of the traditional NSAID) ..................................... 5
Aspirin and a COX-2-selective agent (instead of the traditional NSAID) with a PPI .................. 6
9. How often do you test for H. pylori in patients starting on an NSAID?
Always ...................................................................................................................................................... 5
Usually (more than 50% of the time) .................................................................................................. 4
Sometimes (between 31% and 50% of the time) ............................................................................... 3
Rarely (<30% of the time) ..................................................................................................................... 2
Never ......................................................................................................................................................... 1
10. How often do you test for H. pylori in patients who are already on an NSAID?
Always ...................................................................................................................................................... 5
Usually (more than 50% of the time) .................................................................................................. 4
Sometimes (between 31% and 50% of the time) ............................................................................... 3
Rarely (<30% of the time) ..................................................................................................................... 2
Never ......................................................................................................................................................... 1
11. Thinking about when you prescribe NSAIDs, what percent of the NSAID prescriptions that you prescribe are
traditional NSAIDs (e.g. ibuprofen) and what percent are COX-2-selective agents (e.g. Celebrex, Vioxx or Bextra)?
Traditional NSAIDs ........................................................................................................... __________%
COX-2-selective agents .............................................................................................................. _____%
MUST EQUAL 100%
II. Attitudes and beliefs
12. Which of the following do you believe to be true regarding NSAID use (including aspirin) in individuals
over the age of 70?
Less than 30% use an NSAID at least once per week ....................................................................... 1
Between 30% and 50% use an NSAID at least once per week ....................................................... 2
More than 50% use an NSAID at least once per week ..................................................................... 3
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13. Do you feel that traditional NSAIDs are associated with an increased risk of bleeding from lesions in the
small intestine and/or colon?
Yes ............................................................................................................................................................. 1
No .............................................................................................................................................................. 2
14. Which statement do you feel best characterizes the relationship between NSAIDs and H. pylori?
The presence of H. pylori reduces the likelihood of ulcers in NSAID users ................................. 1
The presence of H. pylori has no effect on the likelihood of ulcers in NSAID users .................. 2
The presence of H. pylori increases the likelihood of ulcers in NSAID users ............................... 3
15. For each of the medications you see listed below, please indicate how likely you feel each is to cause ulcers
and complications such as bleeding






16. How do you feel the use of low-dose aspirin influences the GI safety benefit of the COX-2-selective agents?
Would you say that low-dose aspirin:
Increases the GI safety benefit .............................................................................................................. 1
Decreases the GI safety benefit ............................................................................................................. 2
Has no effect on the GI safety benefit ................................................................................................ 3
17. How much do you associate Vioxx (rofecoxib) with a higher likelihood of MI compared to other
COX-2-selective agents? Please use a scale of 1–10 where a 10 means that the likelihood is significantly
higher and 1 means that there is no difference in the likelihood of MI compared with other COX-2-selective
agents.
Significantly more likely 10 9 8 7 6 5 4 3 2 No more likely than other COX-2-selective agents 1
18. How much influence does concern about potential cardiac effects have on your decision to prescribe Vioxx
(rofecoxib)? Please use a scale of 1–10 where a 10 means that it is extremely influential and 1 means that it does
not influence you at all.
Extremely influential 10 9 8 7 6 5 4 3 2 No influence at all 1
19. For the next question we have listed several statements. Please read each statement carefully and indicate
whether you feel that statement is true or false.
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True False
The majority of patients who develop an upper gastrointestinal bleed as a consequence of an
NSAID-related ulcer have experienced antecedent dyspeptic symptoms.
Low-dose aspirin has been shown to be effective in the primary (no previous history of
infarction) prevention of MI.
Low-dose aspirin has been shown to be effective in the primary prevention of stroke.
Enteric coating or buffering of aspirin reduces the likelihood of developing a serious upper
GI-bleeding event.
Compared with traditional NSAIDs, COX-2-selective agents reduce the likelihood of signifi-
cant adverse GI events such as bleeding, perforation, or obstruction.
The likelihood of significant adverse GI events such as bleeding, perforation, or obstruction is
reduced in a patient taking a COX-2-selective agents plus low-dose aspirin compared to a









H2RA Histamine-2-receptor sntagonist (e.g. Zantac)
COX-2-selective
agents
A class of NSAIDs also referred to as COX-2 inhibitors (e.g. Vioxx)
NSAID For purposes of this research the general term NSAID refers to both traditional NSAIDs and
COX-2-selective agents.
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